Control of virus-induced lymphoproliferation: Epstein-Barr virus-induced lymphoproliferation and host immunity.
Epstein-Barr virus (EBV) is a latent herpesvirus that is associated with a number of tumors. EBV-infected cells show three patterns of latency ranging from type 1, where only one EBV-encoded antigen is expressed, to type 3, where all nine latent cycle proteins encoded by EBV are expressed. Malignancies exhibiting the type 3 latency pattern are highly immunogenic and occur only in immunocompromised patients. It has recently been shown that adoptive immunotherapy with EBV-specific cytotoxic T lymphocytes is an effective therapy for such tumors. Immunotherapy strategies and approaches to increase tumor immunogenicity are now being evaluated in tumors expressing type 2 latency.
Rooney
C M
CM
Department of Virology, St Jude Children's Research Hospital, Memphis, TN 38105, USA. cliona.rooney@stjude.org
Smith
C A
CA
Heslop
H E
HE
D000818:Animals; D006566:Herpesviridae Infections / Q000276:immunology / Q000628:therapy*; D004854:Herpesvirus 4, Human / Q000235:genetics / Q000276:immunology*; D006801:Humans; D016867:Immunocompromised Host; D007167:Immunotherapy; D008232:Lymphoproliferative Disorders / Q000276:immunology / Q000821:virology*; D014412:Tumor Virus Infections / Q000276:immunology / Q000628:therapy*; D017735:Virus Latency